Intelligent Life Sciences
A blueprint for creating value through AI-driven transformation
Explore how AI is revolutionizing life sciences, from accelerating drug discovery to streamlining operations across finance, procurement, and supply chain management.
How AI is reshaping life sciences: Driving innovation while balancing speed, impact, and accountability
AI is revolutionizing life sciences by transforming how organizations innovate, operate, and deliver value. From accelerating drug discovery and optimizing clinical trials to streamlining supply chains and enhancing patient engagement, AI is evolving rapidly—from traditional analytics to generative and agentic AI. These advancements are reshaping scientific and commercial functions, enabling smarter, faster, and more personalized healthcare solutions.
Agentic AI in life sciences: A new frontier in autonomous innovation
Agentic AI is ushering in a new era for life sciences—moving beyond traditional AI to systems that can make decisions, adapt to change, and manage complex tasks on their own. This breakthrough is set to transform R&D, clinical trials, and operations across the industry, with far-reaching impact in pharmaceuticals, biotechnology, and MedTech.
In pharmaceuticals and biotechnology, AI will:
| Automatically design experiments, refine trial protocols, and adjust to new data in real time — speeding up product development |
| Manage regulatory documentation independently, align submissions with changing global guidelines, and adapt strategies based on agency feedback — reducing approval times and compliance risks |
| Continuously analyze patient data, personalize treatment plans, recommend dose changes, and flag safety concerns for specific groups — improving effectiveness and safety after launch |
In MedTech, AI will:
| Power smart devices that self-calibrate and guide care workflows — helping clinicians and patients make informed decisions |
| Detect anomalies, escalate urgent findings, and trigger next steps in care — transforming chronic condition management and post-surgery monitoring |
| Predict component wear, schedule maintenance, and adjust device settings — maximizing uptime, cutting costs, and ensuring reliable clinical performance |
As life sciences leaders push the boundaries of their AI initiatives, they are also tasked with articulating the value these investments bring. They must align AI’s capabilities with their comprehensive business and talent strategies, clearly indicating where value is created at each stage, balancing investment with tangible outcomes that advance patient care, data management, and operational excellence.
Kristin Pothier
KPMG U.S. Life Sciences Sector Leader
Charting the future of US life sciences: Navigating pressures and unlocking potential
KPMG surveyed 163 senior executives across eight countries to understand how life sciences leaders are preparing for AI-driven transformation. The US life sciences sector is quickly adopting AI, but organizations face real challenges as they transform. Shareholders are pushing for fast, measurable returns, which can make it hard to prioritize long-term innovation. Early benefits like cost savings and better data management are emerging, yet significant revenue growth remains out of reach for most. Despite these hurdles, there’s strong optimism about AI’s potential to boost competitiveness and efficiency. As investment grows, those able to adapt and manage these pressures are likely to lead and stand out in the industry.
Key findings at a glance
Key findings are highlighted below. Detailed findings are available in the full report.
AI momentum in life sciences: Urgency, impact, and opportunity
How life sciences organizations are using AI: Platforms, solutions, and adoption trends
From promise to priority: US life sciences organizations ramp up AI spending
AI adoption in life sciences: Progress, gaps, and what’s next
The journey to becoming an intelligent life sciences organization involves three critical phases: Enable, Embed, and Evolve.
Life sciences organizations are moving forward with AI, but progress isn’t uniform across the sector. Our research shows that different teams and functions are at varying stages of adoption—some are focused on building foundational efficiencies, others are scaling AI for growth, and a few are exploring truly transformative opportunities. The journey to AI value is not linear, and organizations may find themselves enabling, embedding, or evolving AI at different speeds depending on their priorities and readiness.
Top 10 areas of opportunity: Life sciences
Download the full Report
AI is rapidly advancing in life sciences—from generative models to autonomous agentic systems that manage trials and adapt in real time. Discover pivotal insights from our latest survey, revealing how AI can empower your workforce, streamline operations, and drive growth. Stay competitive and lead the next generation of life sciences by integrating AI deeply into your business. Download the full report and start your transformation journey today.
Unlocking AI potential: GenAI sector value reports
"The intelligent enterprise: A blueprint for creating value through AI-driven transformation" reports provide a detailed guide for organizations to implement AI, optimize operations, and enhance market impact. Released in a series, the reports will cover eight critical industry sectors and outline a three-phase AI transformation process: Enable, Embed, and Evolve. Insights stem from in-depth interviews with AI experts, sector-specific KPMG professionals, and a survey of 1,390 decision-makers across eight global markets, including Australia, China, Germany, the UK, Canada, France, Japan, and the US. This research offers actionable strategies tailored to each industry sector.
Our latest AI insights
Explore our latest thinking on how to realize the many benefits of integrating AI across your life sciences organization.
Insight
Trusted AI: Powering life sciences breakthroughs
Explore AI's impact on life sciences and learn to balance innovation with ethics for responsible AI adoption in our latest KPMG paper.
Insight
KPMG 2025 Healthcare & Life Sciences Investment Outlook
Our annual in-depth examination of the healthcare and life sciences deal market explores 2024 and the year ahead.
Insight
KPMG global tech report: Life sciences insights
Beyond the hype: Balancing speed, security and value
Insight
Navigating the Complex Landscape of Product Labeling
Ensuring Compliance for Medical Device Manufacturers and Pharmaceutical Companies
Get in touch
Start the conversation. Connect with our team today to learn how we can help you realize the full potential of GenAI.
